Hjorth S, Clark D, Svensson K, Carlsson A, Thorberg O
J Neural Transm. 1985;64(3-4):187-98. doi: 10.1007/BF01256466.
The effects of sub-chronic treatment with (-)-3-PPP (8 mg/kg, s.c., b.i.d. for 21 days), a dopaminergic agent with mixed agonist/antagonist properties, were investigated by means of behavioural and in vivo biochemical methods. There was no change in basal locomotor activity and central dopamine (DA) synthesis after 24 hours withdrawal. A slight, though significant reduction of the locomotor suppressive effect and of the DA synthesis-stimulating effect of acute (-)-3-PPP challenge doses of 0.125 and 1.0 mg/kg (s.c.), respectively, were demonstrated in (-)-3-PPP-pretreated as compared to vehicle-pretreated rats. No change in either action was evident after acute challenge with 8.0 mg/kg (s.c.) of the drug. The plasma levels of (-)-3-PPP were virtually unchanged by pretreatment with active drug. The findings are discussed in terms of a modest down- and up-regulation of DA autoreceptors and postsynaptic receptors, respectively, induced by the subchronic (-)-3-PPP treatment.
采用行为学和体内生化方法,研究了具有混合激动剂/拮抗剂特性的多巴胺能药物(-)-3-苯基哌嗪(8毫克/千克,皮下注射,每日两次,共21天)亚慢性治疗的效果。停药24小时后,基础运动活性和中枢多巴胺(DA)合成无变化。与溶剂预处理的大鼠相比,在(-)-3-苯基哌嗪预处理的大鼠中,分别给予0.125和1.0毫克/千克(皮下注射)的急性(-)-3-苯基哌嗪激发剂量后,运动抑制作用和DA合成刺激作用虽有轻微但显著降低。用8.0毫克/千克(皮下注射)该药物进行急性激发后,两种作用均无明显变化。活性药物预处理对(-)-3-苯基哌嗪的血浆水平几乎没有影响。根据亚慢性(-)-3-苯基哌嗪治疗分别诱导的DA自身受体和突触后受体适度下调和上调来讨论这些发现。